» LEARN MORE ABOUT COVID-19 VACCINES, TESTING, VISITOR & SAFETY REQUIREMENTS

MyHealth

Manage your account, request prescriptions, set up appointments & more.

LOG IN
Don't have an account
Contact Us
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label

SWOG S1802

Trial

Clinical Trial Title

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer)

Trial Status

Open to Enrollment

Start Date

September 17, 2018

Trial Type

Cancer - Adult Oncology

Specific Condition

Prostate cencer

Description

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.

Eligibility Criteria

Eligibility Criteria

  • All patients must have a histologically or cytologically proven diagnosis of adenocarcinoma of the prostate.
  • Patients must have an intact prostate. No prior local therapy for prostate adenocarcinoma is allowed
  • Patients must have technetium bone scan, and either CT of abdomen & pelvis or a MRI of pelvis within 42 days prior to starting standard systemic therapy, with evidence of metastatic disease on at least one scan.
  • Patients with known brain metastases are not eligible.
  • Patients must have received no more than 28 weeks of SST.
  • No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, adequately treated Stage 0, I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for three years.

Please contact Legacy Oncology Research for additional study inclusion/exclusion information.

 

IRB Number

Central IRB

Principal Investigator Name

Jacqueline Vuky, MD

Contact Name

Oncology Clinical Research

Phone

503-413-8199

Contact Fax

503-413-6920

Contact E-Mail

oncologyresearch@lhs.org

Last Updated: Wednesday, January 27, 2021 12:57:01 PM